Loading company…
Oculgen develops large-molecule therapies for serious eye diseases.
Oculgen researches and develops ophthalmic therapies for conditions including age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and glaucoma. Its core product OCUL10 received clinical approval from FDA and CDE. Founded in 2022, it is based in Shenzhen, China, and raised over CNY 100 million in Series A funding in January 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in